Introduction
============

Renal cell carcinoma (RCC) is the one of the most common types of kidney tumor, and remains a major global medical problem despite the numerous new treatment options available [@B1]. Among these RCCs, the most common subtype is clear cell RCC (ccRCC) [@B2]. Despite the novel, targeted immune drug therapy has increased the prognosis of patients, elucidating the mechanism of RCC remains vital. Blocking the interaction between programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) has been shown to improve the prognosis of RCC [@B3], whilst promoting T-cell proliferation and survival by using high-doses of interleukin-2 has an objective response in approximately 10-25 % of patients [@B4]. These results reflect the sensitivity of RCC to immunotherapy. RCC is often accompanied by the tumor-infiltrating immune cells (TIICs), including macrophages and lymphocytes [@B5]. Infiltration by lymphocytes is an immune reaction associated with the elimination of cancer cells and thus improved prognosis in most cancers, including lung cancer, colorectal cancer, and ovarian cancer [@B6]. However, higher levels of tumor-infiltrating lymphocytes usually indicates a poor prognosis and reduced survival in RCC [@B7], [@B8]. These findings suggest that the tumor microenvironment plays a crucial role in the occurrence and development of RCC.

The tumor microenvironment consists of immune cells, mesenchymal cells, endothelial cells, extracellular matrix (ECM) molecules, and inflammatory mediators [@B9]. Studies have shown that the tumor microenvironment affects the gene expression of tumor tissues and patient outcome, and therefore has a diagnostic and prognostic value for tumors [@B10]-[@B13]. Immune and stromal cells make up the non-tumor components of the tumor microenvironment. The ESTIMATE (Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data) algorithm has been developed to predict tumor purity using gene expression data [@B12]. By analyzing the specific gene expression signature of a tumor, ESTIMATE can calculate immune cell and stromal cell scores to predict non-tumor cell infiltration. Other specific gene expression signature-based algorithms have been shown to be effective when applied to colon cancer [@B14], breast cancer [@B15], prostate cancer [@B16] and glioblastoma [@B13]. Furthermore, a newly computational algorithm, CIBERSORT, was used to enumerate 22 immune cell subsets based on 547 key genes, and could reveal the several TIICs expression levels in different groups.

Several prognostic factors are currently available for RCC, including tumor staging, lymph node involvement, histological subtypes, and Fuhrman grading which are gold standard to predict the prognosis of RCC. Despite these biomarkers were used for early detection or prognosis, we still needed another biomarkers to enlarge the prognosis network of RCC [@B17]. The Cancer Genome Atlas (TCGA) has been established to map the genome variations of human cancers using genomic analysis techniques, providing a wealth of clinical and expression profile data [@B18], [@B19]. In this study, we used the dataset of patients with ccRCC from the TCGA database, ESTIMATE algorithm to evaluate the effect of non-tumor cell infiltration on prognosis, identifying a series of microenvironment-related genes, and CIBERSORT algorithm to quantify the proportions of immune cells.

In this study, we identified CXCL13 is associated with TIICs and prognosis of ccRCC patients. And GSEA analysis showed CXCL13 might play an important role in tumor migration.

Materials and Methods
=====================

Database and identification of microenvironment-associated genes
----------------------------------------------------------------

The gene expression profiles and clinical data of patients with ccRCC was obtained from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>) and the ESTIMATE algorithm was used to calculate immune cell and stromal cell scores from the downloaded data. Data analysis was performed using the R software package, limma [@B20]. A fold change of \> 1.5 and false discovery rate (FDR) of \< 0.05 were used as cutoffs to identify differentially expressed genes (DEGs). Volcano plots and heat maps were generated using the ggplot2 and pheatmap packages, respectively, whilst the Venn diagram package was used to identify overlapping genes.

DEG enrichment analysis and protein-protein interaction (PPI) network construction
----------------------------------------------------------------------------------

Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using DAVID (The Database for Annotation, Visualization and Integrated Discovery) [@B21]. An FDR of \< 0.05 was used as the cut-off value. The STRING database [@B22] and cytoscape software [@B23] were used to retrieve and reconstruct a PPI network. Important nodes and subnetworks were predicted and explored using cytohubba, a cytoscape plugin [@B24], and the top 10 hub genes were selected from the results of each method.

Assessment of immune cell type fractions
----------------------------------------

To quantify the proportions of immune cells in the ccRCC samples, the analytical tool called CIBERSORT and the LM22 gene signature were used in this study (<https://cibersortx.stanford.edu/>). The LM22 gene signature contains 547 genes that distinguish 22 human hematopoietic cell phenotypes, with the analysis conducted with 1,000 permutations [@B25]. These TIICs included B cells (memory and naïve B cells), dendritic cells(activated and resting dendritic cells), macrophages (M0, M1 and M2 macrophages), 7 T-cell types (T follicular helper cells, resting memory CD4^+^ T cells, activated memory CD4^+^ T cells, naïve CD4^+^ T cells, gamma delta T cells, CD8^+^ T cells and T regulatory cells), natural killer cells (resting natural killer and activated NK cells), mast cells (resting and activated mast cells), monocytes, plasma cells, neutrophils and eosinophils. The CIBERSORT values generated were defined as immune cell infiltration fraction per sample. For each sample, the sum of 22 evaluated immune cell type fractions equaled 1.

TIMER Database analysis
-----------------------

TIMER is a comprehensive resource for systematic analysis of immune infiltrates across diverse cancer types (<https://cistrome.shinyapps.io/timer/>) [@B26]. It applies a deconvolution previously published statistical method to infer the abundance of TIICs from TCGA cohort, including 10,897 samples across 32 cancer types [@B27].

Oncomine Database analysis
--------------------------

The expression level of CXCL13 in ccRCC was identified in the Oncomine database (<https://www.oncomine.org/resource/login.html>) [@B28]. The threshold was determined according to the following values: p value of 0.05, fold change of 2.0.

Gene set enrichment analysis (GSEA) analysis
--------------------------------------------

GSEA was used to further understand CXCL13-related pathways. The expression level of CXCL13 was used as the phenotype annotation and ccRCC patients in the TCGA cohort were dichotomized into low and high categories. GSEA version 3.0 software ([www.broadinstitute.org/gsea](http://www.broadinstitute.org/gsea)) was used to analyze data. The Molecular Signatures Database (MSigDB) of c5 (c5.all.v6.2.symbols.gmt) was used to assess the functional differences [@B29], [@B30]. FDR \< 0.01 was used as the cut-off criteria.

Cell culture and reagents
-------------------------

All cells were obtained from ATCC. 786-O and OS-RC-2 cells were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (Gibco). Recombinant human CXCL13 was purchased from PeproTech.

Wound healing and transwell assay
---------------------------------

Cell migration was determined by wound healing assay. Briefly, CXCL13-treated and control cells in 6-well plates were wounded by using sterile 200 μl pipette tip for 20h. The speed of wound closure was determined by Photograph. Meanwhile, polycarbonate membrane filters of the chamber were used for the transwell assay. 200 μl cells suspension at a density of 5×10^5^ cells/ml in serum-free medium were seeded into the upper part of the chamber. And the lower chamber was filled with 600 μl medium containing 10% fetal bovine serum. After 24 h of incubation at 37 °C, and the migrated cells adhered to the bottom of the upper chamber were fixed in methanol and stained with crystal violet, photographed and counted via Image J.

Statistical analysis
--------------------

The Statistical Package for Social Science (SPSS version 23.0) program was performed in this study. To investigate potential risk factors for overall mortality, a log-rank test was performed during Kaplan-Meier survival analysis. Correlation analysis was assessed by using chi-square test and Pearson\'s correlation coefficient test. The two-tailed p value was used in this study, and a p value of \<0.05 considered statistically significant (\* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001 and \*\*\*\* p\<0.0001).

Results
=======

Immune cell and stromal cell scores are associated with renal cell carcinoma survival
-------------------------------------------------------------------------------------

In this study, the clinical information and gene expression profiles of 530 patients with RCC were downloaded from the TCGA database. Of these patients, 188 (35.5 %) were females and 342 (64.5 %) were males, while 265 (50 %) cases were stage I, 55 (10.3 %) were stage II, 124 (23.4 %) were stage III, 83 (15.7 %) were stage IV, and 3 (0.6 %) were of unknown stage. The ESTIMATE algorithm was used to calculate immune cell and stromal cell scores to predict the infiltration of non-tumor cells. Next, we divided the patients with RCC into high- and low-score groups based on the median immune cell and stromal cell scores. The clinicopathologic characteristics of the 530 patients are shown in Table [1](#T1){ref-type="table"}. Kaplan-Meier survival analysis revealed that patients with low immune cell scores had a higher survival rate than those with high immune cell scores (Figure [1](#F1){ref-type="fig"}A). Similarly, patients with lower stromal cell scores had increased overall survival (Figure [1](#F1){ref-type="fig"}B), although there was no statistically significant difference. Next, we analyzed the relationship between these scores and clinical stage, revealing that immune cell scores were higher in patients with a higher pathological stage (Figure [1](#F1){ref-type="fig"}C).

Comparison of the gene expression profiles of patients with RCC with different immune cell and stromal cell scores
------------------------------------------------------------------------------------------------------------------

Patients were divided into low- and high-immune cell score groups and their gene expression profiles were analyzed to identify DEGs with corrected P-values \< 0.05 and FDRs \> 1.5. A total of 1369 DEGs (988 up-regulated and 381 down-regulated) were identified (Figure [2](#F2){ref-type="fig"}A) and visualized using a heatmap (Figure [2](#F2){ref-type="fig"}B). Using a similar method with the stromal cell scores, 1564 DEGs (1061 up-regulated and 503 down-regulated) were identified (Figure [2](#F2){ref-type="fig"}C, D). The co-regulated DEGs (377 co-upregulated and 144 co-downregulated) were visualized using Venn diagrams (Figure [2](#F2){ref-type="fig"}E).

GO and KEGG pathway enrichment analysis of DEGs
-----------------------------------------------

To determine the functions of the 521 DEGs, we performed GO enrichment analysis; the top 10 GO terms are shown in Figure [3](#F3){ref-type="fig"}A. DEGs were enriched for T cell activation, immune response-regulating cell surface receptor signaling pathway, and positive regulation of cytokine production in the biological process category, the external side of the plasma membrane, secretory granule membrane, and extracellular matrix in the cellular component category, and cytokine activity, cytokine binding, and cytokine receptor activity in the molecular function category. We also performed KEGG pathway enrichment analysis to determine the pathways most enriched for DEGs, which included cytokine-cytokine receptor interactions, chemokine signaling pathways, and the PI3K-AKT signaling pathway (Figure [3](#F3){ref-type="fig"}B).

PPI network analysis and identification of prognosis-associated genes
---------------------------------------------------------------------

To explore the relationships between the DEGs, The Search Tool for the Retrieval of Interacting Genes (STRING) database and Cytoscape software were used to construct a PPI network for the DEGs (Figure [4](#F4){ref-type="fig"}A). The important nodes and subnetworks of the PPI were predicted and explored using CytoHubba; the 10 most significant node genes were ADCY7, GPR55, CCR4, GNG8, GNB4, C3, CCL21, CCR7, CCL19, and CXCL13.

Since high levels of immune cell infiltration can reduce RCC prognosis, we identified genes affecting the prognosis of patients with RCC among top 10 hub genes. As shown in Figure [4](#F4){ref-type="fig"}B-D, CCR4, GNG8 and CXCL13 were associated with prognosis of ccRCC patients.

The distribution of TIICs in ccRCC according to CXCL13 expression level
-----------------------------------------------------------------------

ccRCC patients from TCGA was divided into low (bottom 10% lowest-expressing CXCL13 samples) and high CXCL13 (top 10% highest-expressing CXCL13 samples) expression group. The differences between 22 subpopulations of TIICs in two groups were investigated using the CIBERSORT algorithm. We evaluated the average proportion of each immune cell type. Figure [5](#F5){ref-type="fig"}A was shown the details of the distribution of TIICs in both groups. There were large differences in the composition of TIICs in two groups. The results revealed that macrophages M1 cells were highly present in high CXCL13 ccRCC tissues, as well as plasma cells, CD4^+^ memory activated T cells, CD8^+^ T cells, follicular helper T cells, gamma delta T cells and Tregs (p\<0.05). Moreover, the proportion of naïve B cells, macrophages M2 cells, resting mast cells, monocytes, resting NK cells and CD4^+^ memory resting T cells was higher in low CXCL13 expression tissues compared to high CXCL13 expression tissues (p\<0.05).

To further determine the correlation between CXCL13 and TIICs, ESTIMATE was used to evaluate immune score. As shown in Figure [6](#F6){ref-type="fig"}A, strong correlation was found in ESTIMATE score, stromal score and immune score (r=0.538, 0.244 and 0.663, respectively). TIMER analysis was used to clarify the correlation of CXCL13 expression with immune infiltration level in ccRCC, and the results revealed that CXCL13 expression was significantly negatively related to tumor purity and had significant positive correlations with infiltrating levels of B cells, CD8^+^ T cells, CD4^+^ T cells, macrophages, neutrophils, and dendritic cells (Figure [6](#F6){ref-type="fig"}B). Additionally, we analyzed the correlation between CXCL13 expression and immune marker genes of immune cells (Table [2](#T2){ref-type="table"}), and we found that the expression levels of most marker sets of immune cells are correlated with CXCL13, except for M1 macrophage, natural killer cell, Th2 and Th17 cells.

Identification of CXCL13 associated biological pathways
-------------------------------------------------------

To further evaluate CXCL13 expression in various cancers, the differential CXCL13 expression between the tumor and normal tissues across all TCGA cohorts was shown in Figure [7](#F7){ref-type="fig"}A. Furthermore, CXCL13 expression was significantly higher in ccRCC (Figure [7](#F7){ref-type="fig"}B). Furthermore, CXCL13 was positively associated with tumor stage and tumor grade (Figure [7](#F7){ref-type="fig"}C-D). Additionally, CXCL13 mRNA levels in ccRCCs were analyzed using the Oncomine database. The results showed CXCL13 expression was higher in tumor tissues, compared to the normal tissues (Figure [7](#F7){ref-type="fig"}E-G).

According to the different CXCL13 expression levels, GSEA analysis, a robust computational method that determines whether the defined set of genes shows statistically significant differences, was used to determine biologic characteristics. Immune response and cell adhesion were enriched significantly, indicating that CXCL13 might play a vital role in these biological processes in ccRCC (Figure [7](#F7){ref-type="fig"}H-I).

CXCL13 promotes migration ability in renal cell lines
-----------------------------------------------------

To identify the effects of CXCL13 on the motility of RCC, wound healing assays were performed in 786-O and OS-RC-2 cells. The results showed that treatment with CXCL13 (50 ng/ml) significant increased the speed of wound closure in both cell lines (Figure [8](#F8){ref-type="fig"}A-D). Transwell assay showed a great increased migrating cells in CXCL13 treated cells (50 ng/ml), compared to control cells (Figure [8](#F8){ref-type="fig"}E-F). Taken together, these results indicated that CXCL13 significantly promoted the migration ability of RCC.

Discussion
==========

TCGA is an open access database which uses a genome-wide approach to reveal the genetic characteristics of cancers. Many studies of cancers such as RCC have screened diagnostic and prognostic biomarkers using TCGA [@B31], [@B32]. Previous studies have shown that intrinsic tumor genes can cause changes in the tumor microenvironment [@B33], [@B34], which affect the occurrence and development of tumors, tumor progression, drug resistance, and overall prognosis [@B35]-[@B37]. The RCC tumor microenvironment is unlike that of other tumor types [@B38]; in most cancers, increased CD8^+^ T cell density is associated with improved prognosis [@B6], yet in RCC increased CD8^+^ T cell density is often associated with a worse outcome [@B39]. A previous study which performed clustering analyses on the infiltrating immune cells in RCC, revealed a total of 17 macrophage and 22 T cell subsets [@B40]. Therefore, the tumor immune microenvironment appears to play an important role in the occurrence and development of RCC.

In this study, we calculated immune cell and stromal cell scores using the ESTIMATE algorithm, finding that patients with a high immune cell score were likely to have a poor prognosis. Next, we identified 521 co-DEGs by comparing the gene expression of patients with high immune cell and stromal cell scores against those with low immune cell and stromal cell scores. GO term analysis revealed that the co-DEGs functions mainly involved the tumor microenvironment, such as T cell activation, immune response-regulating cell surface receptor signaling pathway, positive regulation of cytokine production, and cytokine activity. KEGG pathway enrichment analysis showed that the DEGs were enriched in cytokine-cytokine receptor interactions and the chemokine signaling pathway. Functional enrichment analysis confirmed that these DEGs were closely related to the RCC microenvironment. Next, we performed PPI network analysis and found 10 microenvironment-associated hub genes, including GPR55, CCR4, C3, CCL21, CCR7, CCL19, and CXCL13, which have been reported to promote proliferation, angiogenesis, migration, and invasiveness by altering the tumor microenvironment [@B41]-[@B44], and identified CCR4, GNG8 and CXCL13 were associated with prognosis of ccRCC patients. Furthermore, we evaluated the correlation between TIICs and CXCL13 and CXCL13 mRNA expression in ccRCC. GESA analysis enriched immune response and cell adhesion pathway, indicating that CXCL13 had potential role in tumor migration.

Chemokines are a family of chemotactic cytokines or ligands, which were related to direct migration of immune cells and tumor cells [@B45], [@B46]. CXCL13, and its receptor, CXCR5 (CXCL13/CXCR5 axis), serve as an important pathway of tumor proliferation and metastasis [@B47]-[@B49]. Previous studies demonstrated that CXCL13 upregulation was regarded as a biomarker for poor prognosis in various cancers, including ccRCC [@B50]-[@B52]. Since high immune cell and stromal cell scores are associated with poor prognosis of ccRCC patients, we identified tumor microenvironment-associated genes that correlated with the prognosis of patients with ccRCC. We identified CXCL13 was associated with TIICs and enhanced the effect of migration.

Cancer cells are usually recognized by immune system, including innate and adaptive immunity. And the immune surveillance is driven by a network of mediators, such as cytokines and chemokines, et al [@B53]. On one hand, chemokines regulate tumor microenvironment and initiation of antitumor immune response. On the other hand, chemokines could recruit immune-suppressive regulators and immunoinhibitory mediators to make immune escape. This means CXCL13 could act as a tumor-specific biomarker.

Previous studies had demonstrated that CXCL13 was associated with epithelial-to-mesenchymal transition (EMT) and could activate CXCR5/ERK pathway in breast cancer [@B48], [@B49]. EMT is an important way highly associated with cell adhesion. Dysregulation of cell adhesion was associated with cancer progression and metastasis through promoting the motility of tumor cells and migration into adjacent tissues or invade vascular to distinct organs. Consistent with our results, CXCL13 expression level was positively correlated with immune response and cell adhesion by GSEA analysis. Wound healing and transwell assays showed CXCL13 promoted the migration ability in RCC.

However, there were several limitations in this study. First, the results analysis from TCGA have not detected in GEO database. Second, the detailed functions and potential mechanisms of CXCL13 in ccRCC are needed to be validated *in vitro* and *in vivo* experiment, which would be conducted in our further studies.

Conclusions
===========

In summary, we produced a list of tumor microenvironment-related genes and identified CXCL13 expression level correlated with poor prognosis and increased TIICs of ccRCC. Therefore, CXCL13 likely plays an important role in immune cell infiltration, acts as a prognosis biomarker in patients with ccRCC and has potential role in tumor migration. However, our findings need to be validated in future studies.
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![Immune cell and stromal cell scores are associated with renal cell carcinoma (RCC) survival (**A**) Patients with RCC were divided into two groups based on their immune cell scores. As shown in the Kaplan-Meier survival curve, patients with low immune cell scores had a higher overall survival than those with high immune cell scores (hazard ratio \[HR\] 1.372; 95 % CI 1.01-1.864; *P* = 0.0430 by log-rank test). (**B**) In a similar manner, patients with RCC were divided into two groups based on their stromal cell scores. The Kaplan-Meier survival curve shows no statistically significant difference between the two groups (*P* = 0.2547 by log-rank test). (**C**) Immune cell scores were higher in patients with a higher pathological stage. (^\*\*\*^*P* \< 0.001, by one-way ANOVA followed by Tukey\'s multiple-comparison post-hoc test). (**D**) The stromal cell scores showed no statistically significant differences at different pathological stages.](ijmsv17p1610g001){#F1}

![Gene expression profile comparison of patients with RCC with different immune cell and stromal cell scores (**A-B**) The volcano plot and heatmap show the 1369 genes (988 up-regulated and 381 down-regulated) identified based on the immune cell scores. (**C-D**) The volcano plot and heatmap show the 1564 genes (1061 up-regulated and 503 down-regulated) identified based on the stromal cell scores. (**E**) Venn diagrams show the 377 co-upregulated and 144 co-downregulated genes.](ijmsv17p1610g002){#F2}

![Functional enrichment analysis of DEGs (**A**) Top 10 biological process, cellular component, and molecular function terms for the co-DEGs. (**B**) KEGG pathways enriched for the co-DEGs.](ijmsv17p1610g003){#F3}

![PPI network analysis and identification of prognosis-associated genes (**A**) Protein-protein interaction networks of the co-DEGs. (**B-D**) Kaplan-Meier plotters and log-rank tests for the prognostic value of DEGs. (B) CC4, (C) GNG8, (D) CXCL13.](ijmsv17p1610g004){#F4}

![The landscape of immune infiltration in ccRCC (**A**) The difference of immune infiltration between top 10% highest-expressing and bottom 10% lowest-expressing CXCL13 samples. (**B**) The quantified contrast of the distribution of TIIC subtypes between top 10% highest-expressing and bottom 10% lowest-expressing CXCL13 samples \*p \< 0.05; \*\*p \< 0.01, \*\*\*p\<0.001.](ijmsv17p1610g005){#F5}

![Correlation of CXCL13 expression with immune infiltration level in ccRCC. (**A**) The correlation of CXCL13 with ESTIMATE score, stromal score and immune score. (**B**) CXCL13 expression is significantly negatively related to tumor purity and has significant positive correlations with infiltrating levels of B cells, CD8^+^ T cells, CD4^+^ T cells, macrophages, neutrophils, and dendritic cells.](ijmsv17p1610g006){#F6}

![CXCL13 expression levels in ccRCC (**A**) Human CXCL13 expression levels in different types of tumor from TCGA database were determined by TIMER analysis. (**B**) CXCL13 expression level between non-tumor tissues and tumor tissues from ccRCC. (**C**) CXCL13 expression level among different tumor stages. (**D**) CXCL13 expression level among different tumor grades. (**E-G**) CXCL13 mRNA expression level in Oncomine database. (**H-I**) GSEA plot showed CXCL13 expression associated with immune response and cell adhesion processes \*p \< 0.05; \*\*p \< 0.01, \*\*\*p\<0.001.](ijmsv17p1610g007){#F7}

![CXCL13 promote the migration ability of RCC. (**A-D**) The wound healing assays were used to examine the relative migration ability of CXCL13. Wound closure was observed after 20h. The normalized wound area of control cells at 0 h was set as 1. (**E-F**) Migration of 786-O and OS-RC-2 cells were measured by the transwell migration assay. Transwell assay was observed after 24h \*\*p \< 0.01, \*\*\*p\<0.001.](ijmsv17p1610g008){#F8}

###### 

Patient characteristics and pathologic features

                                Immune scores   *P*-value     StromalScore   *P*-value                   
  ------------ ---------------- --------------- ------------- -------------- ------------- ------------- -------
  Variables    Total patients   low             high                         low           high          
  **Age**      60.56± 12.14     60.77± 12.15    60.35±12.14                  62.38±11.96   58.75±12.06   
                                                0.931                                      0.003         
  \<60         245              122             123                          105           140           
  ≥60          285              143             142                          160           125           
  **Gender**                                                  0.069                                      0.084
  female       186              103             83                           103           83            
  male         344              162             182                          162           182           
  **Stage**                                                   0.011                                      0.11
  stage I      265              151             114                          132           133           
  stage II     56               25              31                           37            20            
  stage III    123              55              68                           59            64            
  stage IV     82               32              50                           37            45            
  unknown      3                1               2                            0             3             

###### 

The association with immune cell markers and CXCL13 expression level

  Description           Gene marker       r          P
  --------------------- ----------------- ---------- ----------
  CD8+ T cell           CD8A              0.5756     \*\*\*\*
                        CD8B              0.5212     \*\*\*\*
  T cell (general)      CD3D              0.589      \*\*\*\*
                        CD3E              0.6135     \*\*\*\*
                        CD2               0.6021     \*\*\*\*
  B cell                CD19              0.6094     \*\*\*\*
                        CD79A             0.4251     \*\*\*\*
  Monocyte              CD86              0.3852     \*\*\*\*
                        CD115 (CSF1R)     0.3022     \*\*\*\*
  M1 Macrophage         INOS (NOS2)       -0.06597   ns
                        COX2(PTGS2)       -0.0151    ns
  M2 Macrophage         CD163             0.2232     \*\*\*\*
                        VSIG4             0.3423     \*\*\*\*
                        MS4A4A            0.3002     \*\*\*\*
  Neutrophils           CD66b (CEACAM8)   0.008424   ns
                        CD11b (ITGAM)     0.04541    ns
  Natural killer cell   KIR2DL1           -0.03222   ns
                        KIR2DL3           0.05152    ns
                        KIR2DL4           0.3342     ns
                        KIR3DL1           -0.0444    ns
                        KIR3DL2           0.0731     ns
                        KIR3DL3           0.05221    ns
  Dendritic cell        HLA-DPB1          0.2912     \*\*\*\*
                        HLA-DQB1          0.2099     \*\*\*\*
                        HLA-DRA           0.2839     \*\*\*\*
                        HLA-DPA1          0.2647     \*\*\*\*
  Th1                   T-bet (TBX21)     0.4259     \*\*\*\*
                        STAT4             0.4852     \*\*\*\*
                        STAT1             0.4578     \*\*\*\*
                        IFN-γ (IFNG)      0.6612     \*\*\*\*
  Th2                   GATA3             0.0744     ns
                        STAT6             -0.05662   ns
                        IL13              0.1663     \*\*\*
  Tfh                   BCL6              0.05778    ns
                        IL21              0.4444     \*\*\*\*
  Th17                  STAT3             0.02595    ns
                        IL17A             0.01578    ns
  Treg                  FOXP3             0.5057     \*\*\*\*
                        CCR8              0.383      \*\*\*\*
                        TGFβ (TGFB1)      0.2035     \*\*\*\*
  T cell exhaustion     PD-1 (PDCD1)      0.6266     \*\*\*\*
                        CTLA4             0.6144     \*\*\*\*
                        LAG3              0.6436     \*\*\*\*
                        GZMB              0.5386     \*\*\*\*
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